Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples

Sora, Daniela Iuliana; Udrescu, Stefan; Albu, Florin; David, Víctor; Medvedovici, Andrei

doi:10.1016/j.jpba.2010.03.004

Cited by 37 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The concentrations of furosemide were analyzed using a modified LC-MS/MS method reported by Sora et al [21]. Thirty μL of rat plasma samples, calibration standards, and QC samples were vortex-mixed with 100 μL of 4-hydroxydiclofenac- d 4 in methanol (500 ng/mL, IS) for 3 min at a high speed.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo

Song

Kong

Jeong

et al. 2014

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundDrug transporters play important roles in the absorption, distribution, and elimination of drugs and thereby, modulate drug efficacy and toxicity. With a growing use of poly pharmacy, concurrent administration of herbal extracts that modulate transporter activities with drugs can cause serious adverse reactions. Therefore, prediction and evaluation of drug-drug interaction potential is important in the clinic and in the drug development process. DA-9801, comprising a mixed extract of Dioscoreae rhizoma and Dioscorea nipponica Makino, is a new standardized extract currently being evaluated for diabetic peripheral neuropathy in a phase II clinical study.MethodThe inhibitory effects of DA-9801 on the transport functions of organic cation transporter (OCT)1, OCT2, organic anion transporter (OAT)1, OAT3, organic anion transporting polypeptide (OATP)1B1, OATP1B3, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) were investigated in HEK293 or LLC-PK1 cells. The effects of DA-9801 on the pharmacokinetics of relevant substrate drugs of these transporters were also examined in vivo in rats.ResultsDA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801. To investigate whether this inhibitory effect of DA-9801 on OCT1, OCT2, and OAT3 could change the pharmacokinetics of their substrates in vivo, we measured the pharmacokinetics of cimetidine, a substrate for OCT1, OCT2, and OAT3, and of furosemide, a substrate for OAT1 and OAT3, by co-administration of DA-9801 at a single oral dose of 1,000 mg/kg. Pre-dose of DA-9801 5 min or 2 h prior to cimetidine administration decreased the Cmax of cimetidine in rats. However, DA-9801 did not affect the elimination parameters such as half-life, clearance, or amount excreted in the urine, suggesting that it did not inhibit elimination process of cimetidine, which is governed by OCT1, OCT2, and OAT3. Moreover, DA-9801 did not affect the pharmacokinetic characteristics of furosemide, as evidenced by its unchanged pharmacokinetic parameters.ConclusionInhibitory effects of DA-9801 on OCT1, OCT2, and OAT3 observed in vitro may not necessarily translate into in vivo herb-drug interactions in rats even at its maximum effective dose.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo

Song

Kong

Jeong

et al. 2014

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…However, a key step of proposing a reliable assay method for determining canrenone and 11- α -hydroxy-canrenone was necessary to evaluate productivity of 11- α -hydroxy-canrenone, consuming rate of canrenone, and biotransformating yield. However, few references were provided for simultaneously determining 11- α -hydroxy-canrenone and canrenone in biotransformation by high-performance liquid chromatography (HPLC), but few related works dealing with the simultaneous quantitation of spironolactone and canrenone in human [15–18] and rat [19] plasma samples, in urine samples [20, 21], or in tablets [22]. Similar structure between 11- α -hydroxy-canrenone and canrenone also increases the difficulties for accurate determination of the two substances by the other methods such as colorimetry or thin-layer chromatography (TLC).…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Identification and Quantification of Canrenone and 11‐α‐Hydroxy‐Canrenone by LC‐MS and HPLC‐UVD

Huang

Zhang

Cui

et al. 2011

BioMed Research International

View full text Add to dashboard Cite

A procedure for simultaneous identification and quantification of canrenone and its biotransformed product 11-α-hydroxy-canrenone by high-performance liquid chromatography with ultraviolet detector (HPLC-UVD) and mass spectrometry (LC-MS) methods was proposed. The optimal determination variables on the HPLC-UVD or LC-MS coupled with a ZORBAX Eclipse XDB-C18 column (150 mm × 4.6 mm, 5 μm) were set as follows: detection wavelength of 280 nm, mobile phase of water and methanol gradient elution, temperature for the chromatographic column of 30°C, flow rate of mobile phase of 0.8 mL/min, sample injection volume of 5 μL, and elution time of 40 min. The MS conditions were set as follows: the flow rate of sheath gas, aux gas, and sweep gas were kept at 35 arb, 5 arb, and 0 arb, respectively. The temperature of capillary was held at 300°C, and capillary voltage was set at 30.00 V. Tube lens were performed at 100.00 V. The proposed method was validated by linearity (r2 ≥ 0.9910), average recovery (94.93%, RSD1.21%), precision (RSD ≤ 1.31%), limit of detection, and limit of quantification (LOD 0.1~0.12 mg/L, LOQ 0.5~0.67 mg/L), which proved to be affordable for simultaneously determining canrenone and its bio-transformed product 11-α-hydroxy-canrenone.

show abstract

“…Compared with other methods, the proposed method provides short analysis time, simple procedure, and can be used as microextraction technique for routine analysis in clinical laboratories . It can be deduced that the proposed method allows the achievement of quantitative extraction efficiencies for drugs and their metabolites by using the lowest amount of organic solvent and a reduced sample preparation time.…”

Section: Discussionmentioning

confidence: 99%

A new and fast strategy based on semiautomatic microextraction by packed sorbent followed by ultra high performance liquid chromatography for the analysis of drugs and their metabolites in human urine

Magiera

Baranowska

2014

J. Sep. Science

View full text Add to dashboard Cite

A novel analytical approach has been developed for the determination of selected drugs (milrinone, enalapril, carvedilol, spironolactone, acenocumarol, ticlopidine, cilazapril) and their metabolites (2-oxoticlopidine, cilazaprilat, canrenone, 5'-hydroxycarvedilol, O-desmethyl-carvedilol, enalaprilat) in human urine, based on a miniaturized extraction technique; semiautomatic microextraction by packed sorbent, using a new digitally controlled syringe, followed by ultra high pressure liquid chromatography separation combined with UV detection. During method optimization, the extraction parameters as the type of sorbent material, type and volume of elution solution, number of extraction cycles, volume and pH of sample, type and volume of washing solution were studied. The chromatographic separation of the target analytes was performed with a core-shell analytical column using 0.05% trifluoroacetic acid in water and acetonitrile in gradient elution mode. The limits of quantification ranged from 0.016 to 0.045 μg/mL. Under the optimized conditions, extraction efficiency was higher than 70.1% for drugs and their metabolites. Due to its simplicity and speed, this method was successfully applied to the quantitation of selected compounds in urine samples.

show abstract

Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples

Cited by 37 publications

References 21 publications

Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo

Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo

Simultaneous Identification and Quantification of Canrenone and 11‐α‐Hydroxy‐Canrenone by LC‐MS and HPLC‐UVD

A new and fast strategy based on semiautomatic microextraction by packed sorbent followed by ultra high performance liquid chromatography for the analysis of drugs and their metabolites in human urine

Contact Info

Product

Resources

About